New User:

Forgot your password?

Stock Market & Financial Investment News

News For INTC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 20, 2015
10:04 EDTINTCActive equity options trading on open
Subscribe for More Information
10:00 EDTINTCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: (FLWS) upgraded to Buy from Hold at Noble Financial... Diageo (DEO) upgraded to Overweight from Neutral at JPMorgan... Dollar General (DG) upgraded to Buy from Hold at BB&T... Intel (INTC) upgraded on positive checks at JMP Securities... Mazor Robotics (MZOR) upgraded to Buy from Neutral at Sterne Agee CRT... Star Bulk Carriers (SBLK) upgraded to Neutral from Sell at UBS... Trimble (TRMB) upgraded to Buy from Neutral at Goldman.
07:22 EDTINTCIntel upgraded on positive checks at JMP Securities
As noted earlier, JMP Securities upgraded Intel to Outperform from Market Perform. After conducting checks, the firm thinks the company is benefiting from strengthening cloud prospects and diminishing execution risk. JMP believes that Intel has made significant progress on server chips, is in the midst of an earnings trough, and is poised to reported higher revenue and margins in 2016. Target $45.
07:21 EDTINTCIntel confident of sales growth despite PC chip sales decline, says UBS
UBS came away from Intel's analyst meeting believing the company is confident it can continue to grow sales despite declining PC chip sales. The firm cited expectations for continued growth of data center sales and better than expected operating expense management. UBS reiterated its Buy rating and raised its price target to $39 from $37 on Intel shares.
06:18 EDTINTCIntel upgraded to Outperform from Market Perform at JMP Securities
Subscribe for More Information
November 19, 2015
16:23 EDTINTCOn The Fly: Top stock stories for Thursday
The major averages spent most of the day in a narrow range bouncing around the flatline, seeming content to consolidate the gains from their rally of the last three days. The market internals confirmed the lackluster session, as the number of advancing stocks were generally in line with declining stocks. Oil prices remained under pressure for much of the session, but closed the day little changed, similar to equities. ECONOMIC EVENTS: In the U.S., jobless claims are still near four-decade lows, with 271,000 first-time claims filed in the week ended November 14. The Philly Fed index rose 6.4 points to 1.9 in November, better than the forecast for a -0.5 reading. In Europe, minutes from the most recent European Central Bank policy meeting showed that some participants called for more stimulus amid deflation risks, weak oil prices and a sluggish recovery in the regions' economy. In Asia, the Bank of Japan maintained its current pace of monetary stimulus, as expected. COMPANY NEWS: The biggest U.S. health insurer said this morning that it is considering pulling out of Obamacare due to losses it has suffered from its participation in the program and cut its profit outlook for this fiscal year, sending its shares and those of its industry peers lower. UnitedHealth (UNH) fell $6.62, or 5.65%, to $110.63 after trimming its fiscal 2015 earnings outlook, citing the Affordable Care Act, and stating that it is "evaluating the viability of the insurance exchange product segment." Meanwhile, Aetna (AET) declined 6.5%, Humana (HUM) dropped 4%, Anthem (ANTM) declined almost 7% and Cigna (CI) slid over 5% following their rival's announcement. Hospital stocks fell as well, with HCA Holdings (HCA), LifePoint (LPNT), Community Health (CYH) and Tenet (THC) all ending the day lower by 6% or more... Last night, Bloomberg reported that Pfizer (PFE) is nearing an agreement to acquire Allergan (AGN) for $370 to $380 per share, citing people familiar with the matter. CNBC's David Faber then reported that deal talks are in the "final innings" and centered on an all stock transaction whereby Pfizer would offer 11-plus shares per Allergan share. Then, people close to the talks told Financial Times that the U.S. drugmaker is preparing to offer more than $380 per share for Allergan. Amid all these reports, Treasury Secretary Jacob Lew said that his department will release "targeted guidance" later this week meant to "deter and reduce further the economic benefits of corporate inversions" like the one being contemplated by the drugmakers. Government intervention concerns appeared to trump the pricing reports, as Allergan closed the day 2.8% lower at $301.73, while Pfizer fell 3% to $32.29 per share... Intel (INTC) rose 3.4% to $34.30 after the chipmaking giant hosted its annual investor meeting, at which it announced an increase to its dividend and guided for "mid-single digits" percentage revenue growth in fiscal 2016. MAJOR MOVERS: Among the notable gainers was Keurig Green Mountain (GMCR), which surged $7.38, or 18.22%, to $47.88 after it reported better than expected quarterly earnings and guided for fiscal 2016. Also higher was Square (SQ), which rose $4.07, or 45%, to close its first day as a publicly-traded company at $13.07 after pricing its initial public offering at $9 per share. Twitter (TWTR), which, like Square, claims Jack Dorsey as its CEO, gained 1.6% to $26.32 following Square's public debut. Another high-profile tech company also gained in its first day of public trading, as Match Group (MTCH), the owner of dating app Tinder and other online dating services, climbed 22.8% to $14.74 after pricing its IPO at $12 per share. Among the noteworthy losers was Kirkland's (KIRK), which fell nearly 33% to $13.60 after the company reported downbeat quarterly earnings and provided lower than expected guidance. Also lower were shares of AMAG Pharmaceuticals (AMAG), which lost 9.84% to $26.20 after it received a complete response letter from the FDA for its proposed treatment to reduce the risk of preterm birth in at-risk patients. INDEXES: The Dow fell 4.41, or 0.02%, to 17,732.75, the Nasdaq slid 1.56, or 0.03%, to 5,073.64, and the S&P 500 declined 2.34, or 0.11%, to 2,081.24.
16:00 EDTINTCOptions Update; November 19, 2015
Subscribe for More Information
13:17 EDTINTCIntel says growth rate in DCG will be less reliant on Enterprise
13:10 EDTINTCIntel sees FY15 gross margin about 62%
12:50 EDTINTCIntel rises after FY16 outlook
Subscribe for More Information
12:29 EDTINTCIntel raises dividend to $1.04 per share on an annual basis
Subscribe for More Information
12:27 EDTINTCIntel sees FY16 CapEX $10B plus/minus $500M
12:26 EDTINTCIntel sees FY16 gross margin at 62% plus/minus couple of points
Subscribe for More Information
12:25 EDTINTCIntel sees FY16 revenue growth in the mid-single digits, consensus $57.48B
Subscribe for More Information
11:52 EDTINTCIntel sees Altera as accelerator of 'virtuous cycle'
Subscribe for More Information
11:41 EDTINTCIntel says Cloud is key growth area for Data Center
11:32 EDTINTCIntel says Tabet business is not a growth business
Subscribe for More Information
11:24 EDTINTCIntel targets FY15 revenue $55.2B, consensus $55.25B
Comments from Intel Investor Meeting.
07:43 EDTINTCHouse Energy & Commerce Committee to hold a hearing
The Commerce, Manufacturing and Trade Subcommittee holds a hearing entitled, "The Disrupter Series: The Fast-Evolving Uses & Economic Impacts of Drones" with Joshua Walden, Senior Vice President and General Manager of the New Technology Group at Intel on November 19 at 10:15 am. Webcast Link
November 18, 2015
13:44 EDTINTCBefore the Move: Watch Intel into tomorrow's analyst day
Chipmaker Intel's (INTC) analyst day tomorrow could yield information on numerous company operations, but Jefferies analyst Mark Lipacis cautions investors that the probability for positive surprises appears low given recent spending outlays. BACKGROUND: Intel, one of the largest semiconductor makers in the world, is scheduled to hold an analyst day on Thursday, November 19. Beyond providing forecasts for its various business segments and remarks on the larger computer market, Intel is expected to provide further clarity on several recent stories, including its memory joint venture with Micron (MU), plans to invest heavily in a Chinese production facility and progression towards chips on the 10 nanometer scale. STRONG OUTLOOK, MILD MEETING: Intel's pending acquisition of Altera (ALTR) and its plans to invest as much as $5.5B in a computer memory facility in Dalian, China leave little room for positive surprises at tomorrow's event in regards to 2016 margins, capital expenditures, or shareholder returns, Jefferies analyst Mark Lipacis said in a recent research note. That said, the analyst views Intel's Chinese facility expansion as part of a "brilliant investment strategy that positions Intel as a partner to China" and "keeps the market open" to its microprocessors, perhaps Intel's more famed business segment. Though the two initiatives are certain to push up near-term debt load, Lipacis takes the longer-term view, reminding investors that Intel has shown consistently strong free cash flow over the past decade, leading him to forecast another $13B in 2016. The year may also bring "a number" of other positives for the company, including more data center wins after the Altera tie-up, potentially renewed sales on a cyclical uptick in PC gaming, and even the possibility of an iPhone chip contract, though Lipacis said none of those points look set to be discussed tomorrow. The analyst kept a Buy rating and $38 price target on the shares while reiterating that Thursday's Intel event may have little in store for those expecting eye-grabbing surprises. PRICE ACTION: Shares of Intel have advanced roughly 0.9% to $32.92 Wednesday afternoon. "Before the Move" is The Fly's recurring series of exclusive stories that identify potentially market moving events, along with analyst predictions, ahead of the news.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use